0 (216) 358 02 38

turhal@superonline.com

Pazartesi-Cuma 15:30-18:30

21 Ara 2020

BY: serdarturhal

Comments: Yorum yapılmamış

2019 – Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients

Obesity is a well-known carcinogenic factor for colorectal
cancer [1, 2]. However, the relationship between obesity and
malignancy is still not well understood. Obesity can cause
production of VEGF, angiopoietin-2, and other growth factors
that induce tumor growth [3, 4]. It can also cause insulin
resistance, hyperinsulinemia, and increased production of
adipokines and proinflamatory cytokines that may be associated
with tumor progression [5]. A recent study suggested a
link between obesity and sporadic MSI-high colorectal cancer
in women [6]. … Read More

21 Ara 2020

BY: serdarturhal

Comments: Yorum yapılmamış

2018 – Plexin C1 Marks Liver Cancer Cells with Epithelial Phenotype and Is Overexpressed in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the fifth most common
cancer amongman and seventh among woman and ranked as
the third most common cause of cancer-related deaths [1, 2].
Chronic liver injury, Hepatitis B (HBV) and C (HCV) virus
infections, alcohol-associated diseases, and aflatoxin intoxications
are the leading causes of HCC development. Several
mutations affecting WNT/𝛽-Catenin, PI3K/RAS, and oxidative
stress signaling pathways as well as hot spotmutations in
TP53 were frequently observed in hepatocarcinogenesis [3].
Orthotopic liver transplantation (OLT) is the most effective
treatment option for patients with early diagnosis, albeit not
suitable for advanced cases [4]. Despite the approval of two
tyrosine kinase inhibitors, namely, sorafenib and regorafenib,
for advanced cases, 5-year survival of HCC patients is only
less than 20% [1]. … Read More

21 Ara 2020

BY: serdarturhal

Comments: Yorum yapılmamış

2017 – Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Efforts to improve outcomes beyond those achieved with
1 year of trastuzumab in patients with early-stage
HER2-positive breast cancer are ongoing. Several different
approaches, including extending the duration of
trastuzumab to 2 years (HERceptin Adjuvant [HERA]
trial),5 concurrent or sequential administration of lapatinib,
a tyrosine kinase inhibitor, with trastuzumab (Adjuvant
Lapatinib and/or Trastuzumab Treatment Optimisation
[ALTTO] trial),6 and the addition of bevacizumab, an antiangiogenic
agent, to trastuzumab (Bevacizumab with
Trastuzumab Adjuvant Therapy in HER2-Positive Breast
Cancer [BETH] trial)7 have all been unsuccessful, with no
significant disease-free survival benefit compared with
1 year of trastuzumab. APHINITY (Adjuvant Pertuzumab
and Herceptin in Initial Therapy in Breast Cancer) showed
a significant improvement in invasive disease-free survival
at 3 years from the addition of pertuzumab to trastuzumabbased
adjuvant therapy;8 however, the 3-year reduction in
the percentage of patients with recurrence or death with
pertuzumab was only 1% (pertuzumab group, 94%;
placebo group, 93%).8 Thus, the role of pertuzumab as
adjuvant therapy in HER2-positive breast cancer is a
matter of ongoing debate.9 1 year of trastuzumab added to
adjuvant chemotherapy remains the standard of care for
most patients with early-stage HER2-positive breast
cancer;10,11 however, other phase 3 trials addressing the
same question are in progress. … Read More

21 Ara 2020

BY: serdarturhal

Comments: Yorum yapılmamış

2016 – Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study

Renal cell carcinoma (RCC) accounts for approximately 2% of all
cancers.1 On admission, one-third of patients with RCC are at the
metastatic stage.2 Chemotherapy resistance is very high in patients
with RCC.3 Only a limited subset of patients ( 20%) benefit from
cytokine therapy.4-7 It has been shown that the median progressionfree
survival (PFS) was 4.7 months for patients with metastatic RCC
who received interferon alfa as a first-line treatment. … Read More

21 Ara 2020

BY: serdarturhal

Comments: Yorum yapılmamış

2015 – Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Group trial)

Colorectal cancer is among the most common type of cancers worldwide. According to the GLOBOCAN 2008 database, which is published by the International Agency for Research on Cancer to estimate the worldwide incidence and mortality of 27 cancers from 182 countries, colorectal cancer (1.23 million, 9.7% of the total) is the third most commonly diagnosed cancers worldwide following lung (1.61 million, 12.7%) and breast (1.38 million, 10.9%) cancers (1). Although incidence and mortality of colorectal cancers have been decreasing since 1985, the worldwide incidence is still up to 20.4 for men and 14.7 for women with a mortality rate of 9.7 and 7.0 per 100,000 persons per year. In the less developed regions, the incidence of colorectal cancers for men and women is 12.1 and 9.4 per 100,000 persons per year. However, in the developed regions, this incidence for men and women increases to 37.7 and 24.3 per 100,000 persons per year (1,2). Colorectal cancer is the second most common cause of death from any cancer in men in the European Union following the lung cancer (3). … Read More

21 Ara 2020

BY: serdarturhal

Comments: Yorum yapılmamış

2014 – Concurrent chemoradiotherapy with low dose weekly gemcitabine in medically inoperable muscle-invasive bladder cancer patients

Radical cystectomy with pelvic lymphadenectomy has been considered the standard treatment in muscle-invasive bladder cancer patients and 5-year overall survival rates are about 60 %.with this treatment [1] Alternatively, bladderpreserving strategies with maximal transurethral resection of bladder tumor followed by platinum-based chemoradiotherapy has been tested in randomized controlled trials [2–6]. In these studies, the complete response rates reported were 60–90 % and 5-year bladder intact survival rate was 40 % [2, 5, 6].
However, in medically inoperable patients, concomitant therapy may be more challenging due to the risk of enhanced toxicity. Unfortunately, in retrospective series single modality radiotherapy or chemotherapy failed to … Read More

21 Ara 2020

BY: serdarturhal

Comments: Yorum yapılmamış

2013 – Results of Adjuvant FOLFOX Regimens in Stage III Colorectal Cancer Patients: Retrospective Analysis of 667 Patients

Colorectal cancer is the fifth leading cause of cancer death worldwide [1] . Worldwide, colorectal cancer accounted for approximately 1.2 million new cancer cases in 2008 [2, 3] . Surgical resection is the only curative treatment
for locoregional disease, but 40–50% of patients have recurrences and or metastasis and die of metastatic disease [4] . The benefits of 5-fluorouracil (5-FU)-based adjuvant chemotherapy in reducing recurrence and prolonging
survival are well established, especially for stage III disease, and this has become the standard of care worldwide [5–10]. … Read More

BY: serdarturhal

Comments: Yorum yapılmamış

2012 – ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

Colorectal cancer (CRC) is the most commonly diagnosed cancer in Europe and one of the leading causes of cancer death worldwide [1, 2]. In the past years treatment and outcome of early and advanced disease has steadily improved. Progress in imaging enables more precise differentiation of prognostic
subgroups in rectal cancer and a selected treatment approach based on tumour–node–metastasis (TNM) stage and potential mesorectal fascia (MRF) involvement to improve local control. Even in metastatic disease some patients with metastases limited to liver and/or lung can be cured with a multi-modal treatment approach of intensive chemotherapy, followed by secondary R0-resection of initially unresectable disease. Currently, a broad variety of trials and retrospective analyses gave further insights into clinical questions like selection and duration of treatment, combinations with targeted agents and tailored treatment with respect to clinical and molecular factors. In addition, knowledge of prognostic as well as
predictive biomarkers (blood, tumour tissue) is significantly increasing to better guide selection of drugs and treatment strategy. … Read More

21 Ara 2020

BY: serdarturhal

Comments: Yorum yapılmamış

2011 – Weight gain after adjuvant chemotherapy in patients with early breast cancer in Istanbul Turkey

Weight gain is a well-known and unwanted complication of adjuvant chemotherapy in breast cancer. We observed that the female Turkish cancer patients frequently gain weight with adjuvant treatment of breast cancer and planned to examine the magnitude of this problem in early breast cancer patients treated at our hospital. A total of 176 early breast cancer patients who received their adjuvant systemic therapy in Marmara University Hospital between 2003 and 2007 are included in the study. … Read More

21 Ara 2020

BY: serdarturhal

Comments: Yorum yapılmamış

2010- Factors that Affect Patients’ Decision-Making about Mastectomy or Breast Conserving Surgery, and the Psychological Effect of this Choice on Breast Cancer Patients

treatment is surgery, with breast conserving surgery (BCS) being widely used for early-stage disease. Due to changes in body image, depressive symptoms can occur after surgery. Here, we evaluate factors that affect patients’ decision on surgery, and investigate differences in the level of depression after mastectomy or
BCS in a population of Turkish patients. … Read More

  • 1
  • 2